Sanofi Announces New, Global Business Unit Structure
Sanofi's new business-unit structure focuses on growth drivers.
Sanofi announced plans on July 15, 2015 to evolve its business with the creation of five, global business units: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur, and Merial. This new structure will be implemented beginning in January 2016, following required legal and social consultation.
"The new organization simplifies and focuses Sanofi to optimize growth," said Olivier Brandicourt, CEO, Sanofi. "This is a necessary step for ensuring that Sanofi's new medicines and vaccines continue to build on our heritage of providing innovative healthcare therapies."
The General Medicines & Emerging Markets Global Business Unit will be led by Peter Guenter and will consist of Sanofi's established products, generics, consumer healthcare, and all pharmaceutical businesses in emerging markets.
The Specialty Care Global Business Unit, to be called Sanofi Genzyme, will be led by David Meeker and will consist of Sanofi's medicines in rare diseases, multiple sclerosis, oncology, and immunology, including the two, investigational biologics, sarilumab and dupilumab.
The Diabetes & Cardiovascular Global Business Unit will be led by Pascale Witz and will consist of Sanofi's Diabetes Care medicines as well as Cardiovascular, including Praluent (alirocumab), which is currently under review by FDA and the European Medicines Agency.
Sanofi Pasteur and Merial are both Global Business Units and will continue to manage their current portfolios of vaccines and animal health products. Olivier Charmeil will continue to lead Sanofi Pasteur, and Carsten Hellmann will continue to lead Merial.
The composition of the Executive Committee remains unchanged.
Source: Sanofi
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
